Traditional antibody drug discovery methods are wet-lab based, lengthy, non-standard, non-scalable and make use of animals.
The project solves all these problems with a computer-based method. The company's vision is to bring more drugs to market at an unprecedented speed by digitalising the whole drug discovery and development process.
The idea is built on three pillars of drug discovery, machine learning and automation, which naturally attracted a biologist, an engineer and a developer. The team started with a developer and grew organically to include a biologist and an engineer as the needs arose.